Jay Tuttle

1.7k total citations · 1 hit paper
40 papers, 1.1k citations indexed

About

Jay Tuttle is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Jay Tuttle has authored 40 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 18 papers in Epidemiology and 11 papers in Immunology. Recurrent topics in Jay Tuttle's work include Inflammatory Bowel Disease (20 papers), Microscopic Colitis (18 papers) and Celiac Disease Research and Management (7 papers). Jay Tuttle is often cited by papers focused on Inflammatory Bowel Disease (20 papers), Microscopic Colitis (18 papers) and Celiac Disease Research and Management (7 papers). Jay Tuttle collaborates with scholars based in United States, Canada and Japan. Jay Tuttle's co-authors include Joseph L. Unthank, Michael C. Dalsing, William J. Sandborn, Geert D’Haens, B. Paul Herring, Ryan Nachreiner, Bret A. Connors, Jeff C. Falcone, Toshifumi Hibi∥ and Brian G. Feagan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Jay Tuttle

40 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

2023 74 citations Jay Tuttle, Edit Drescher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jay Tuttle United States	16	390	336	271	212	204	40	1.1k
Iván Ferraz‐Amaro Spain	20	133 0.3×	396 1.2×	216 0.8×	117 0.6×	228 1.1×	144	1.5k
Ann Samnegård Sweden	22	145 0.4×	532 1.6×	405 1.5×	132 0.6×	355 1.7×	27	1.5k
Tünde Tarr Hungary	19	118 0.3×	573 1.7×	129 0.5×	141 0.7×	230 1.1×	61	1.4k
Rachel T. McGrath Australia	15	171 0.4×	154 0.5×	101 0.4×	89 0.4×	153 0.8×	36	999
David Manka United States	16	146 0.4×	514 1.5×	311 1.1×	182 0.9×	481 2.4×	21	1.6k
Erik J. M. Toonen Netherlands	20	112 0.3×	342 1.0×	223 0.8×	78 0.4×	234 1.1×	44	1.0k
Roslynn A. Stirzaker United States	8	125 0.3×	848 2.5×	475 1.8×	171 0.8×	555 2.7×	8	1.8k
Fernanda Genre Spain	21	96 0.2×	447 1.3×	156 0.6×	79 0.4×	381 1.9×	85	1.2k
Joe McIntosh United States	16	143 0.4×	553 1.6×	219 0.8×	175 0.8×	425 2.1×	22	1.5k
Robert C. Bauer United States	18	152 0.4×	243 0.7×	181 0.7×	61 0.3×	507 2.5×	47	1.1k

Countries citing papers authored by Jay Tuttle

Since Specialization

Citations

This map shows the geographic impact of Jay Tuttle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Tuttle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Tuttle more than expected).

Fields of papers citing papers by Jay Tuttle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Tuttle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Tuttle. The network helps show where Jay Tuttle may publish in the future.

Co-authorship network of co-authors of Jay Tuttle

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Tuttle. A scholar is included among the top collaborators of Jay Tuttle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Tuttle. Jay Tuttle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tuttle, Jay, Edit Drescher, Jesus Abraham Simón Campos, et al.. (2023). POS0307 A PHASE 2 TRIAL OF PERESOLIMAB FOR ADULTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 82. 397–397. 1 indexed citations

Dubinsky, Marla C., Vipul Jairath, Brian G. Feagan, et al.. (2023). Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis. BMJ Open Gastroenterology. 10(1). e001115–e001115. 8 indexed citations

Schmitz, Jochen, Nick Powell, Richard E. Higgs, et al.. (2023). Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study. Clinical and Translational Gastroenterology. 14(7). e00578–e00578. 15 indexed citations

Benschop, Robert J., Jay Tuttle, Lin Zhang, et al.. (2022). The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Science Translational Medicine. 14(655). eabn3041–eabn3041. 20 indexed citations

Chua, Lynette J., et al.. (2022). P612 Mirikizumab Pharmacokinetics and Exposure - Efficacy Relationships in Patients with Ulcerative Colitis. Journal of Crohn s and Colitis. 16(Supplement_1). i541–i542. 2 indexed citations

Crisp, Melissa, Nicole L. Kallewaard, Robert J. Benschop, et al.. (2022). The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination. UNC Libraries. 1 indexed citations

Cohen, Max, Ajay Nirula, Mary Marovich, et al.. (2021). Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting. 29(1). 32–33. 4 indexed citations

Sands, Bruce E., Laurent Peyrin‐Biroulet, Jarosław Kierkuś, et al.. (2021). Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease. Gastroenterology. 162(2). 495–508. 109 indexed citations

Schmitz, Jochen, Nick Powell, Klaus Gottlieb, et al.. (2020). DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity. Journal of Crohn s and Colitis. 14(Supplement_1). S103–S104. 3 indexed citations

10.

Bissonnette, Robert, Catherine Maari, Alan Menter, et al.. (2020). 15328 Efficacy and safety of mirikizumab in patients with moderate to severe plaque psoriasis: 104-week results from a randomized phase 2 study. Journal of the American Academy of Dermatology. 83(6). AB147–AB147. 3 indexed citations

11.

Reich, Kristian, Phoebe Rich, Catherine Maari, et al.. (2019). Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study. British Journal of Dermatology. 181(1). 88–95. 57 indexed citations

12.

Sandborn, William J., Marc Ferrante, Bal Raj Bhandari, et al.. (2019). Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 158(3). 537–549.e10. 179 indexed citations

13.

Sands, Bruce E., William J. Sandborn, Laurent Peyrin‐Biroulet, et al.. (2019). 1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease. Gastroenterology. 156(6). S–216. 19 indexed citations

14.

Jairath, Vipul, William J. Sandborn, Yan Dong, et al.. (2019). 709 Optimizing the Definition of Clinical Response Using the Modified Mayo Score: An Analysis of a Phase 2 Study With Mirikizumab in Patients With Ulcerative Colitis. The American Journal of Gastroenterology. 114(1). S417–S417. 1 indexed citations

15.

Vadhan‐Raj, Saroj, Rafat Abonour, Jonathan W. Goldman, et al.. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of Hematology & Oncology. 10(1). 73–73. 75 indexed citations

16.

Rosen, Lee S., Jonathan W. Goldman, Alain P. Algazi, et al.. (2016). A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clinical Cancer Research. 23(8). 1910–1919. 57 indexed citations

17.

Tuttle, Jay, et al.. (2002). Impaired collateral development in mature rats. American Journal of Physiology-Heart and Circulatory Physiology. 283(1). H146–H155. 39 indexed citations

18.

Tuttle, Jay, Harold M. Burkhart, William C. Watson, et al.. (2002). Impaired Collateral Artery Development in Spontaneously Hypertensive Rats. Microcirculation. 9(5). 343–351. 33 indexed citations

19.

Tuttle, Jay, Ryan Nachreiner, Bret A. Connors, et al.. (2001). Shear level influences resistance artery remodeling: wall dimensions, cell density, and eNOS expression. American Journal of Physiology-Heart and Circulatory Physiology. 281(3). H1380–H1389. 204 indexed citations

20.

Tuttle, Jay, et al.. (1995). Effect of Acute Potassium-Magnesium Aspartate Supplementation on Ammonia Concentrations during and after Resistance Training. International Journal of Sport Nutrition. 5(2). 102–109. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact